Gout Drug Associated with Cardiovascular Risk

The gout drug Uloric (febuxostat) appears to have a higher rate of heart-related death when compared with another gout medication, according to a new FDA safety alert.

Following Uloric’s approval in 2009, the FDA required its manufacturer, Takeda Pharmaceuticals, to conduct a postmarket safety trial because clinical trials indicated that patients treated with Uloric had a higher rate of heart-related issues – such as heart attacks, strokes and heart-related deaths – compared to patients taking Zyloprim or Aloprim (allopurinol).

The warnings and precautions section of Uloric’s label notes the risk of cardiovascular events.

The safety trial enrolled 6,000 gout patients treated with either febuxostat or allopurinol. Preliminary results showed there was a higher risk of heart-related death and death from all types of causes in the febuxostat group.

The FDA is not taking any direct action at this time. However, it is urging doctors to consider the results before prescribing Uloric or continuing patients on the drug.


Jonathan Block

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

FDA Recalls Metformin and NP Thyroid

FDA Recalls Metformin and NP Thyroid

The FDA has issued a recall of two drugs–NP Thyroid and Metformin–after testing revealed that they weren’t up to code. Read more below, and if you’re taking either medication, please be sure to contact your doctor for how to continue treatment responsibly.  NP Thyroid Recalled Thirteen lots of NP Thyroid,…

Can Convalescent Plasma Treat COVID-19 Patients?

Can Convalescent Plasma Treat COVID-19 Patients?

One of the most promising treatments for COVID-19 is convalescent plasma, a component of blood. People who have been infected with the virus and are now healthy have developed COVID-19-fighting antibodies, which, the theory is, can be given to people currently sick with COVID-19 so that those antibodies can boost…

  • Advertisement